<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568061</url>
  </required_header>
  <id_info>
    <org_study_id>INOT 44</org_study_id>
    <nct_id>NCT00568061</nct_id>
  </id_info>
  <brief_title>Nitric Oxide in Myocardial Infarction Size</brief_title>
  <acronym>NOMI</acronym>
  <official_title>The Effects of Nitric Oxide for Inhalation on Myocardial Infarction Size</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether or not inhaled nitric oxide can decrease
      myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment
      elevation MI (STEMI) who undergo successful percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the trial is to assess whether or not inhaled nitric oxide can decrease
      myocardial infarction (MI) size as a fraction of left ventricular (LV) size at 48-72 hours in
      patients presenting with an ST segment elevation MI who undergo successful percutaneous
      coronary intervention (PCI).

      The primary endpoint for this study will be myocardial infarction size as a fraction of left
      ventricular size at 48-72 hours as measured by contrast-enhanced cardiac MRI.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size</measure>
    <time_frame>48-72 hours</time_frame>
    <description>The primary endpoint - mean percent of the myocardial infarction size to the fraction of left ventricular size at 48-72 hours was measured by contrast-enhanced cardiac Magnetic Resonance Imaging (MRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MI Size at 48-72 Hours</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI Size Normalized to Area at Risk</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Perfusion at Coronary Angiography</measure>
    <time_frame>at completion of PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infarct Transmurality</measure>
    <time_frame>48-72 hours and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global &amp; Regional LV Function and LV Mass</measure>
    <time_frame>48-72 hours and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global LV Function and Mass</measure>
    <time_frame>between 48-72 hours and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI Size as a Fraction of LV Size</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of ST Segment Elevation Compared With That Observed at Enrollment</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Troponin T Levels and CPK-MB Area Under the Curve</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adverse Remodeling Parameters Compared With 48-72 Hrs: Changes in LV End-diastolic Vol, End-systolic Vol, End-diastolic Myocardial Wall Thickness in Infarct, Peri-infarct and Remote Areas, and in Sphericity Index at End-diastole and End-systole</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>ST Elevation MI</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>NO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitric oxide for inhalation</intervention_name>
    <description>MI size at 48-72 hours</description>
    <arm_group_label>NO</arm_group_label>
    <other_name>INOmax®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction and electrocardiographic evidence of ST elevation

          -  No clinical evidence of congestive heart failure

          -  All patients must undergo successful percutaneous coronary intervention for TIMI 0 or
             1 coronary flow with resulting TIMI 2 or 3 flow

          -  Greater than 18 years of age

          -  Signed IRB approved informed consent

        Exclusion Criteria:

          -  Prior myocardial infarction

          -  Requirement for urgent cardiac surgery

          -  Previous CABG or PCI

          -  Left bundle branch block

          -  Heart block that is expected to require a temporary pacemaker for greater than 72
             hours

          -  Prior use of thrombolytic therapy for the current event

          -  Unable to tolerate magnetic resonance imaging or unable to tolerate gadolinium
             contrast media, including patients with a calculated creatinine clearance less than
             60ml/min/1.73m² BSA

          -  Active or recent hemorrhage requiring an invasive procedure for evaluation or
             transfusion within 6 weeks prior to presentation, or hemorrhagic stroke within the 6
             weeks prior

          -  Neutropenia (WBC &lt;2000 (mm)³), Anemia (HCT &lt;30%, Thrombocytopenia (Thrombocytes
             &lt;50,000 (mm)³). It is not necessary to confirm blood counts prior to start of study
             drug in the absence of clinical suspicion.

          -  Known or suspected aortic dissection.

          -  Prior history of pulmonary disease requiring chronic oxygen therapy.

          -  Pregnancy, lactating, and women of childbearing potential.

          -  Medical problem likely to preclude completion of the study.

          -  Use of investigational drugs or device within the 30 days prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Baldassarre, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac &amp; Vascula Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jack D. Weiler Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeBauer Cardiology</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cardiovascular Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Utah Imaging</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virga Jesse Hospital</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>TGG 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2007</study_first_submitted>
  <study_first_submitted_qc>December 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <results_first_submitted>August 3, 2010</results_first_submitted>
  <results_first_submitted_qc>August 3, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2010</results_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>INOT44</keyword>
  <keyword>NOMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>7 medical centers enrolled subjects. A total of 29 subjects were enrolled in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide administered at 80ppm</description>
        </group>
        <group group_id="P2">
          <title>Nitrogen Gas</title>
          <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inclusion / exclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide administered at 80ppm</description>
        </group>
        <group group_id="B2">
          <title>Nitrogen Gas</title>
          <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="11.71"/>
                    <measurement group_id="B2" value="63.8" spread="12.41"/>
                    <measurement group_id="B3" value="63.1" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size</title>
        <description>The primary endpoint - mean percent of the myocardial infarction size to the fraction of left ventricular size at 48-72 hours was measured by contrast-enhanced cardiac Magnetic Resonance Imaging (MRI).</description>
        <time_frame>48-72 hours</time_frame>
        <population>Analysis was per intent to treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Inhaled Nitric Oxide</title>
            <description>Inhaled Nitric Oxide administered at 80ppm</description>
          </group>
          <group group_id="O2">
            <title>Nitrogen Gas</title>
            <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent of Myocardial Infarction Size to the Fraction of Left Ventricular Size</title>
          <description>The primary endpoint - mean percent of the myocardial infarction size to the fraction of left ventricular size at 48-72 hours was measured by contrast-enhanced cardiac Magnetic Resonance Imaging (MRI).</description>
          <population>Analysis was per intent to treat population</population>
          <units>percent of myocardial infarction size</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="8.99"/>
                    <measurement group_id="O2" value="12.5" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MI Size at 48-72 Hours</title>
        <time_frame>48-72 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MI Size Normalized to Area at Risk</title>
        <time_frame>48-72 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Perfusion at Coronary Angiography</title>
        <time_frame>at completion of PCI</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infarct Transmurality</title>
        <time_frame>48-72 hours and 4 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global &amp; Regional LV Function and LV Mass</title>
        <time_frame>48-72 hours and 4 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Global LV Function and Mass</title>
        <time_frame>between 48-72 hours and 4 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MI Size as a Fraction of LV Size</title>
        <time_frame>4 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Resolution of ST Segment Elevation Compared With That Observed at Enrollment</title>
        <time_frame>4 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Troponin T Levels and CPK-MB Area Under the Curve</title>
        <time_frame>48 hours</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Adverse Remodeling Parameters Compared With 48-72 Hrs: Changes in LV End-diastolic Vol, End-systolic Vol, End-diastolic Myocardial Wall Thickness in Infarct, Peri-infarct and Remote Areas, and in Sphericity Index at End-diastole and End-systole</title>
        <time_frame>4 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Inhaled Nitric Oxide</title>
          <description>Inhaled Nitric Oxide administered at 80ppm</description>
        </group>
        <group group_id="E2">
          <title>Nitrogen Gas</title>
          <description>Nitrogen Gas (Placebo) administered at 80ppm</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retropertioneal Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Baldassarre, MD</name_or_title>
      <organization>INO Therapeutics LLC</organization>
      <phone>908-238-6603</phone>
      <email>james.baldassarre@ikaria.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

